3084244-26-5
Chemical Structure
AU-24118
- CAS No.: 3084244-26-5
- Formula:C37H40N6O4
- Molecular Weight:632.75
InChIKey: KKSYHCQMBAMWOQ-UHFFFAOYSA-N
SMILES: NC1=C(C=C(N=N1)C2=C(C=CC=C2)O)C3=CC=C(C=C3)N4CCC(CC4)N5CCC(CC5)C6=CC=C(C=C6)OC7CCC(NC7=O)=O
Biological Activity: AU-24118 is an orally active PROTAC degrader that recruits cereblon to target the degradation of SMARCA2, SMARCA4 and PBRM1. AU-24118 impairs the chromatin accessibility of oncogenic transcription factors, inhibits colony formation, dislodges chromatin-bound transcription factors, attenuates downstream signal transduction, induces apoptosis, and exerts antiproliferative and cytotoxic effects. AU-24118 can be used in research related to castration-resistant prostate cancer, colorectal cancer, small cell lung cancer and multiple myeloma (including the t (4;14) subtype)[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AU-24118 | 98.82% | AU-24118 is an orally active PROTAC degrader that recruits cereblon to target the degradation of SMARCA2, SMARCA4 and PBRM1. AU-24118 impairs the chromatin accessibility of oncogenic transcription factors, inhibits colony formation, dislodges chromatin-bound transcription factors, attenuates downstream signal transduction, induces apoptosis, and exerts antiproliferative and cytotoxic effects. AU-24118 can be used in research related to castration-resistant prostate cancer, colorectal cancer, small cell lung cancer and multiple myeloma (including the t (4;14) subtype). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. He T, et al. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2024 Apr 09;121(15):e2322563121. [Content Brief]
- [2]. Islam MT, et al. Synthetic lethality between PBRM1 deficiency and PARP inhibitors: exploiting G2/M checkpoint arrest in colorectal cancer. Molecular medicine (Cambridge, Mass.). 2026 Jun 06. [Content Brief]
- [3]. He T, et al. Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. Cancer cell. 2024 Aug 12;42(8):1336-1351.e9. [Content Brief]
- [4]. Yamashita Y, et al. Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes. Blood. 2025;146(Suppl 1):2138-2139.
